Fig. 7

The recommended therapies for R/R DLBCLs. This chat shows the recommended therapies with patients of R/R DLBCL in different clinical states. DLBCL diffuse large B-cell lymphoma, CAR-T chimeric antigen receptor T cells, RT radiotherapy, BSC best supportive care, CR complete response, PR partial response, SD stable disease, PD progressive disease, HDT high-dose chemotherapy, SCT, stem cell transplantation. ¶ second-line chemotherapy for transplant eligible: DHAP ± R, GDP ± R, ICE ± R, ESHAP ± R, GemOx ± R, MINE ± R, § second-line therapy for transplant ineligible: CAR-T (Liso-cel), Pola ± B ± R, Tafa + Len, CEOP ± R, DA-EPOCH ± R, GDP ± R, GemOx ± R, Rituximab, BV, BTKi, Len ± R, † second-line chemotherapy for relapse within 12 months or refractory disease: alternative systemic therapy, Ж, Bridging therapy: DHAP ± R, GDP ± R, ICE ± R, Pola ± B ± R, RT, ξ CAR-T products: Axi-cel, Liso-cel, € CAR-T products: Axi-cel, Liso-cel, Tisa-cel, ₤ ≥ Third-line chemotherapy: alternative systemic therapy